Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01069809 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
A Phase 2 study, sponsored by Argos Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
NCT01069809: Completed Phase 2 study, sponsored by Argos Therapeutics.
NCT01069809 is a Phase 2 study that has completed, run by Argos Therapeutics. The registered enrollment target is 53 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01069809, a Phase 2 study, has completed, sponsored by Argos Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and effectiveness of AGS-004, an immune therapy, for HIV-infected individuals. Safety and effectiveness will be tested while the individuals are both taking antiretroviral therapy (ART) medication and interrupting ART medication.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL AGS-004
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2010-07 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
What the finished NCT01069809 record still lists
NCT01069809 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (60% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01069809 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01069809 about?
NCT01069809 is a clinical study titled "Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption". The purpose of this study is to determine the safety and effectiveness of AGS-004, an immune therapy, for HIV-infected individuals. Safety and effectiveness will be tested while the individuals are both taking antiretroviral therapy (ART) medication and interrupting ART medication.
What is the current status of trial NCT01069809?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2010-07. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01069809?
The interventions under investigation include: Placebo (BIOLOGICAL), AGS-004 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01069809?
This trial is sponsored by Argos Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01069809's enrollment target sits among peer trials
53 1171st of 2000 higher than 820 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia